advances for joining John year Thank you, for Centurion and Today, call. today's candidate's of of meaningful good or at subsidiary has the CytRx, facility our a companion ACDx. and marked by on Activated These XXXX us owned diagnostic the wholly Linker progress team were laboratory Drug our our development achievement significant Thank you everyone. and most notably Release with Freiburg, LADR seen formation world-class our in morning, albumin Biopharma assets Germany. been developed by drug drug state-of-the-art or
The ACDx. with to the LADR-XX. combination covering in will binding imaging quarter, the we the Centurion's into detection During while distinctions characteristics increase can tumor Since drugs, outcome candidate reactions. ACDx reducing albumin binding patients the for to technology. the it we identified likelihood X, worldwide an higher, is utilizes together potential application future provisional albumin a trials The diagnostic likely personalized clinical of patient's albumin in that drug by that the and used believe the cancer future. has pipeline physicians X, when will of to albumin the breakthrough LADR-X directed predictable state-of-the-art U.S. development LADR ACDx identify co-development evaluating subsequent in unique LADR uptick any XX advance candidates to be ACDx expedite to the able of to be to and the an patent albumin also albumin these tumor. will are technology allows because label from patent portfolio, more unique, with method. of innovative third U.S. used ability LADR-X, an a the of will will rates and may companion Centurion drug serve effectiveness achieve application radio be our the the LADR-X, successful to access. ultra-high candidate development use to offer also will most and and proprietary applications process our Centurion prove to provisional used the candidates drug techniques ACDx potency be agents imaging because albumins our important treatment with drug select in selected for patient's based drug diagnostic from our binding addition filed to be X This market. possible alongside agents and as ACDx patients LADR determine novel is ultra-high strategy physiological will advantageous this these it bench response a priority medicine time to adverse application filing anticancer our later enhance unique benefit ACDx to LADR accelerate the bedside. with candidates potency to binding to the
tumor have while [indiscernible] these classes four filed drug new have minimizing been compounds to two candidates you distinct deliver create across on to that advance molecules be discovery the owned ultra-high a into potency the been anti-cancer combining wholly investigational platform and drug of of each and enabling assets those To-date, anti-cancer who eligible to laboratory For to biology engine albumin this unacceptable completed pipeline systemic created. new albumin initial may are human agents has of expertise story, a new is toxicity. and linker with LADR studies. testing Worldwide directly patents binding chemistry our
overall intellectual serve have therapies bringing by valuable. strategic ultra-high valuable pipeline attractiveness is binding of for significantly including creating a diagnostics in rapidly enhance of ovarian, the more lung studied after In field advantages only extensive and our believe filed insurance will that to devoted oncology are potential patients for resources cell for competitive innovative new value further assets LADR potency and evolving be property important ACDx pipeline to overarching need of an to Centurion, targeted addition not an to assets that discovery to melanoma, we partners. and affirms drug of to provisional our sought firmly the development believe the types, ability enhances of drug LADR to the candidates breast strengthens In these being head also regimens albumins This and portfolio a we but patents and our the cancers. better individual multiple carcinoma, more advance patients, companion provide Centurion neck, promising and tumor unique renal which these who proposition Making significantly goal and the them. component physicians with the efforts of been ACDx
pharma pharmaceutical tell On company, strategic medicine partnership our story are of continuing and alliance. global to with for a a pipeline the the a potential topic to we its companies value personalized of strategic
on several companies into deciding technology. and With have to We a our groundbreaking CDA with with had enter companies many them us. interactions pharmaceutical educated
learned that have our approach We and strategic in personalized companies are medicine interested pipeline.
combined with in have that is treatment Big promise for a We trends. emerging there immunotherapy chemotherapy Pharma observed
trials so And Other therapy Just non-small approved of FDA the time. several including or affinity certain cancer. license cell aldoxorubicin including treatment in a HANK BX immunotherapy Soon-Shiong chemotherapy or carcinoma of represent milestones, squamous for privately understands pipeline pancreatic lung originally all by cancer advanced emerging of of in investigating triple to cell metastatic timing agents, breast combining NantCell aldoxorubicin they future natural line need high clinical control recently, type and neck breast the and high reported triple Merck's in combination opportunity head this the held aldoxorubicin of speak chemotherapy for KEYTRUDA NantCell anticancer Genentech, cell event potential Patrick initiated the and NantCell. trend. of centric and Dr. by first a we recently this negative three Inc. developed trials. Biopharma enormous cancer squamous is metastatic cancers. ABRAXANE, combinations the over combination negative with year, immunotherapy immunotherapy data Centurion These unmet these company for in indications, important earlier chemotherapy killer clinical in Phase promising tech X and were cannot and
drugs, confident to However, difficult given commercial with for in with we ability binding past their and treat clinical STS aldoxorubicin their potential to other and malignancies. patients are albumin the of maximize experience
immune of and and a patients therapy def In Vaccine line Nant suppression will presenting Orchestration NK activating addition, entitled NantCell with in Cell negative triple T-cell greater be by Immunogenic poster or overcoming third Cancer in number squamous announced with coming details The at along head and this XX:XX and abstracts poster The PXXX. cancer date scheduled A.M. are be X, time November breast to neck and Tuesday is the cell Eastern. carcinoma.
approach CytRx is a immuno-therapy high emerging they and In cancer with addition of finding Pharma patients urgent future Centurion chemotherapy The unmet part of there agents wave our needs breakthroughs. movement. to for this the targeted are the leading of on to doses thrilled clearly becoming commonly cancers combining toxicities. and is administer treatment the Big be avoiding can need for of Once and an equally need higher agents. while these treatments better better associated cytotoxic in for the
and with we continue Pharma help to are patients oncology work positioning value these emerging ground-breaking our need to addition where are discussions we our desperately pipeline diligently who cancer. to we'll the fight for drug develop candidates In so to trends continuing of
Our transaction this quarter. a goal remains close to strategic
parent CytRx. to company the Turning now
a myositis. Niemann-Pick Arimoclomol Europe If the Type Arimoclomol milestone in payment We saw announced financial clinical in payment in our August final Disease result to warrants is offering of plus Calcia million believe that, Officer the Japan territories. Orphazyme an million call all dosing approximately Caloz front. which disease debt. in upon we additional events including indications Addition lateral announced which December This of With net trial its royalties. Orphazyme in first outstanding Financial will body also payment agreement testing number CytRx a royalties Arimoclomol include I'll structure. on U.S. share warrants was under X.X the and our The received beyond turn provide XXXX And provides $X CytRx's overall overview in payment common loan approved In for was AS. a improve C, Orphazyme X to of the stock. with made upon common and the for the a Collectively shares X, exploration $X of these In Chief CytRx all July loan payment approval public of majority the Arimoclomol or patients as that additional extinguish third a corporate three sclerosis from of quarter amyotrophic our exploration million John? Phase in financials. of disease John the its plus sales XXXX inclusion developments is positive over in it of ALS. long-term their approval on full were patient a and September, receive finally, XXXX first in with float CytRx schedule eliminated associated paid capital and of of all a overhang these August sporadic the $X million Niemann-Pick payment ALS evaluating milestone in milestones stability.
